Condition

Myasthenia Gravis

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 35 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials35

Recruiting9

Common interventions25

Lead sponsors shown15

Clinical trials

35 shown

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesNCT07304154 · 2026-04-10

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune DiseasesNCT06939166 · 2025-06-17

Biomarkers in Autoimmune Disease of Nervous SystemNCT06502015 · 2024-07-31

Cohort Study on Neuroimmune Diseases in the Reproductive AgeNCT07653984 · 2024-04-21

Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic PathologyNCT07136844 · 2024-03-29

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard TherapyNCT06249438 · 2024-03-20

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous SystemNCT04561557 · 2020-09-22

Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)NCT06940323 · 2017-03-21

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at SanfordNCT01793168 · 2010-07-01

Tongji NADs CohortNCT07333196 · 2026-03-01

NOT_YET_RECRUITING

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune DiseasesNCT07392528 · 2026-03-01

NOT_YET_RECRUITING

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune DiseasesNCT06869278 · 2025-06-17

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesNCT06539169 · 2024-06-10

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)NCT06220201 · 2024-03-28

ACTIVE_NOT_RECRUITING

Psychological Health and Adverse Childhood Experiences in Myasthenia Gravis: Online Mental Health BMI Learning ProgramNCT07291713 · 2024-01-10

Depressive Tendency and Counseling Outcomes in Thymoma-Associated MGNCT07649187 · 2024-01-01

Exploring Accessible Beauty for Individuals With Upper Extremity DeficitsNCT05945784 · 2023-07-21

Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and HypertensionNCT06256172 · 2023-06-16

Cognitive Functioning in People With Myasthenia Graivs: Impact on Daily Life Activities, Work, Disability and Quality of LifeNCT06718855 · 2023-06-07

SP Thoracic IDE StudyNCT05150210 · 2022-07-20

ACTIVE_NOT_RECRUITING

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesNCT05635266 · 2021-10-26

Medication Adherence and Non-adherence in Adults With Rare DiseaseNCT04541875 · 2021-01-01

National, Multicentric Registry Study on Neuroimmunological Diseases in ChinaNCT06443333 · 2020-12-01

Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 InfectionNCT04695379 · 2020-04-27

Neurology Inpatient Clinical Education TrialNCT03826056 · 2019-02-01

The Effect of Spinal Stabilization Exercises in Patients With Myasthenia GravisNCT03743740 · 2018-12-03

Myasthenia Gravis and PsycheNCT03205306 · 2017-05-08

Biomarkers in Neural DisordersNCT02761707 · 2016-06-01

Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)NCT02102594 · 2014-10-01

Innovative Measures of Speech and Swallowing Dysfunction in Neurological DisordersNCT02118805 · 2013-10-01

Study of an Intervention to Improve Problem List Accuracy and UseNCT01105923 · 2010-05-01

Exercise for Stable Myasthenia GravisNCT01047761 · 2010-01-01

Autologous Stem Cell Transplant for Neurologic Autoimmune DiseasesNCT00716066 · 2008-06-01

ACTIVE_NOT_RECRUITING

Serum Auto-Antibodies in Neurological DiseasesNCT00704626 · 2002-01-01

ENROLLING_BY_INVITATION

Spontaneous Coronary Artery Dissection (SCAD) and AutoimmunityNCT03941184 · 1995-01-01

Common interventions

Leading sponsors

Tongji Hospital 3 Charite University, Berlin, Germany 2 Tianjin Huanhu Hospital 2 Baltimore VA Medical Center 1 Beth Israel Deaconess Medical Center 1 Brigham and Women's Hospital 1 Casa Colina Hospital and Centers for Healthcare 1 Centre Hospitalier Universitaire de Liege 1 Dartmouth-Hitchcock Medical Center 1 Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta 1 Fred Hutchinson Cancer Center 1 Hacettepe University 1 Intuitive Surgical 1 Jiann-Horng Yeh 1 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 1

Trial status mix

COMPLETED12

RECRUITING9

UNKNOWN5

ACTIVE_NOT_RECRUITING3

NOT_YET_RECRUITING2

WITHDRAWN2

ENROLLING_BY_INVITATION1

TERMINATED1

Phase mix

NA8

PHASE15

EARLY_PHASE13

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.